 NEW YORK , Sept. 1, 2022 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor conferences in September: September 7-8: Citis 17th Annual BioPharma Conference. 